Categories AlphaGraphs, Earnings, LATEST, Retail

Constellation Brands brews earnings beat in Q2

Constellation Brands Inc. (STZ) topped market estimates on sales and earnings for the second quarter of 2019. Shares were up over 3% during premarket hours on Thursday.

The New York-based brewer reported net sales of $2.3 billion, up 10% compared to the same period last year. Net income attributable to Constellation Brands increased 136% to $1.14 billion or $5.87 per share from the prior-year period. Comparable EPS grew 16% to $2.87.

Constellation Brands second quarter 2019 earnings
Constellation Brands Q2 2019 Earnings Infographic

The company posted sales increases in both its Beer and Wine and Spirits divisions. In the beer division, the Modelo and Corona brands drove strong portfolio performance and market share gains with depletion growth of 10%. In the wine and spirits division, net sales benefited from strong shipment volume growth.

For the full year of 2019, the company expects reported EPS to come in the range of $14.10 to $14.25 and comparable EPS to come in the range of $9.60 to $9.75.

The beer business expects net sales and operating income growth of 9% to 11% while the wine and spirits business expects net sales and operating income growth of 2% to 4% for 2019.

On October 3, Constellation declared quarterly cash dividends of $0.74 per share of Class A common stock and $0.67 per share of Class B common stock, payable on November 20 to shareholders of record on November 6.

In August, the company had announced its plan to invest $4 billion in Canopy Growth Corporation, thereby increasing its stake to 38% in the medical marijuana company. The transaction is expected to close by October-end.

Constellation Brands looks to cannabis for a high, ups stake in Canopy

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top